WO1998020858A1 - Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation - Google Patents

Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation Download PDF

Info

Publication number
WO1998020858A1
WO1998020858A1 PCT/SE1997/001901 SE9701901W WO9820858A1 WO 1998020858 A1 WO1998020858 A1 WO 1998020858A1 SE 9701901 W SE9701901 W SE 9701901W WO 9820858 A1 WO9820858 A1 WO 9820858A1
Authority
WO
WIPO (PCT)
Prior art keywords
release
pcms
compact member
active compound
drug
Prior art date
Application number
PCT/SE1997/001901
Other languages
English (en)
Inventor
Torkel Gren
Christer Nyström
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9604124A external-priority patent/SE9604124D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to NZ335737A priority Critical patent/NZ335737A/xx
Priority to AU50758/98A priority patent/AU728754B2/en
Priority to CA002271652A priority patent/CA2271652A1/fr
Priority to EP97913618A priority patent/EP0941069A1/fr
Priority to JP52247998A priority patent/JP2001503766A/ja
Publication of WO1998020858A1 publication Critical patent/WO1998020858A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to a compact member having extended release of an active compound.
  • a tablet based on multiple-units made of porous cellulose matrices (PCMs), and having the property of at the same time being easily handled without being damaged, and having an adequate rate of disintegration.
  • the release rate of the active compound is controllable.
  • Extended release of an active compound e.g. a drug
  • a coating such as a release-controlling, water permeable film or membrane.
  • This technique has been extensively used heretofore in the art. In the process of forming such films or membranes organic solvents are often needed, which from both economic and environmental point of view is undesirable.
  • MU preparations containing a plurality of pellets have been used as carriers of drugs previously.
  • the use of MU drug preparations is considered to promote good absorption properties since they are dispersed over a large area in the gastro- intestinal (Gl) tract. Furthermore, they are considered to have a lower transit rate especially in the colon compared to matrix tablets.
  • MU preparations are preferable to single unit preparations, since they may be divided into smaller portions all having the same release and absorption properties which will give greater flexibility in selection of the dose size. Also, MU preparations will facilitate administration of the drug to patients having problems to swallow and will considerably reduce the risk of dose dumping.
  • Extended release multiple-units based on porous matrices of the type mentioned above, as carriers of drugs have commonly been filled in hard gelatine capsules.
  • MUs Extended release multiple-units
  • the reason for this is the advantages of tablets over the above mentioned capsules, such as more rational production, higher dose accuracy and lower risk of tampering.
  • the release rate is often affected by compaction.
  • the release rate may increase due to crushing, formation of cracks in the release-controlling coating etc., or decrease due to complete or partial failure of tablets to disintegrate. Tablets made of coated multiple-units with intact or nearly intact release rate by the use of relatively large amounts of excipients have been reported.
  • the function of the added excipients may be to protect the film by absorbing energy during compaction or to act as disintegrants.
  • PCMs may e.g. be prepared by a wet or a dry method as disclosed in International Patent Applications WO-A-91/18590 and WO-A-94/23703, respectively, both assigned to Pharmacia & Upjohn AB of Sweden.
  • the preparation of PCMs does not form part of the invention, and will not be specifically discussed herein. Instead, the said patent applications are incorporated by reference.
  • PCMs are normally small spherical particles, so-called pellets, with a diameter in the range of from about 0.5 up to about 1.5 mm, suitably with a diameter of about 1 mm.
  • Other methods for making pellets of cellulose, optionally incorporating one or more additional substances, e.g. lipids could be extrusion/spheronization, "layering", melt-pelletization and spray-cooling.
  • Extrusion/spheronization is performed by pressing a moistured powder mass through a metal sheet wherein a plurality of holes has been made. The mass thereby forms spaghetti-like threads. These threads are transferred to a horizontally rotating plate, where they are broken to pieces and formed to spheres which subsequently are allowed to dry.
  • PCMs Porous cellulose matrices
  • MU multiple-unit
  • a possible method to modify the drug release rate from non-compacted PCMs is by incorporating release-modifying substances together with the drug into the pores of the cellulose matrix, as disclosed in WO-A-91/18590.
  • thermoplastic materials could be used as release modifiers, the incorporation could be done by making use of such materials in a molten state. It might then be possible that the process be carried out without excessive energy input or organic solvents. Especially if the drug could be incorporated by suspending it in or otherwise mix it with the melted release modifier, this process could be very cost effective.
  • Non-compacted PCMs have been shown to extend the release of paracetamol incorporated together with lipids in the matrix pores.
  • This type of spherical extended release pellets could be produced very cost effectively with low energy consumption and without any organic solvents.
  • Another possible advantage of this type of system is that drug release from matrix pellets of this type may be less sensitive to compression than pellets coated with a thin membrane. It also seems reasonable that the disintegrating effect of cellulose could be advantageous when trying to compact PCMs into disinte-grating multiple-unit tablets.
  • MUs are commonly delivered in doses contained in hard gelatine capsules. It would be desirable to be able to manufacture tablets by compression of MUs, because manufacture would thereby become more cost effective, tablets would be more easily divided in subdoses etc. However, MUs are difficult to make into tablets by compression since
  • the compact members can be given an in-vitro dissolution rate which is essentially the same as that exhibited by the uncompacted pellets of which the compact member consist. This means that the amount of drug released does not deviate more than ⁇ 50 % of the total amount of drug in the compact member, at any time.
  • the compact member suitably contains talc, as claimed in claim 6.
  • the release rate may be controlled by varying the talc content. Thereby, the release rate of the active compound can be practically equal to the release rate of free PCMs.
  • Fig. 1 is a graph showing radial tensile strength for tablets according to the invention (filled circles) and tablets of empty PCMs (open squares) as a function of compaction pressure
  • Fig. 2 is a graph showing disintegration time for tablets according to the invention as a function of compaction pressure
  • Fig. 3 is a graph showing release of drug from pellets not according to the invention as a function of time for different lipid compositions
  • Fig. 4 is a graph showing release of drug from tablets according to the invention as a function of time at two different compaction pressures using two in-vitro dissolution methods;
  • Fig. 5 is a graph showing release of drug for tablets according to the invention as a function of time at five different compaction pressures and for uncompacted pellets;
  • Fig. 6 is a graph showing the effect of talc on release of drug of a tablet according to the invention (tablet of granules and 5 % (w/w) talc (open triangles), tablets without any talc (filled circles)) and uncompressed granules as a reference (X).
  • Drug release from PCMs has, as mentioned above, been shown to be possible to extend over at least 16 hours by incorporating release modifiers together with the drug into the pores in the cellulose matrix.
  • the rate of release could be adjusted by varying the release modifier composition, drug concentration and particle size of the PCMs.
  • the release seems to be controlled by diffusion from the matrix but is also affected by the distribution of drug in the matrices and an increase of porosity due to erosion of matrix material and pores formed by the swelling of cellulose.
  • the incorporation of drug and release modifier could be performed simultaneously by dispersing a micronized drug into the molten release modifiers.
  • an extended release multiple-unit preparation may be prepared from PCMs with a simple, solvent-free, one-step process.
  • Materials suitable as release-modifying agents are characterized by exhibiting a low melting point, a low viscosity above the melting point and a low solubility in water.
  • the material is suitably only slightly soluble in water and preferably insoluble in water.
  • Lipids may be suitable as release modifiers for incorporation into PCMs, since they are often low-melting, non-toxic, relatively inexpensive and there is a broad range of lipids with different physico-chemical properties. Lipids may be classified on the basis of their different interaction with water into non-polar lipids (e.g. aliphatic hydrocarbons) and polar lipids. The polar lipids could be further subdivided into different classes: I) insoluble nonswelling amphiphilic lipids, II) insoluble swelling amphiphilic lipids and III) soluble amphiphilic lipids, where the solubility refers to water as a medium.
  • non-polar lipids e.g. aliphatic hydrocarbons
  • polar lipids could be further subdivided into different classes: I) insoluble nonswelling amphiphilic lipids, II) insoluble swelling amphiphilic lipids and III) soluble amphiphilic lipids, where the solubility refers
  • the release rate from lipophilic matrices can often be controlled by the use of a mixture of a nonpolar and a polar lipid or of two polar lipids from different classes.
  • lipid There is no universal definition of "lipid". Lipids are sometimes defined as naturally occurring fats, oils and waxes. However, here the word lipid is used in a broader sense covering also e.g. aliphatic hydrocarbons and fatty alcohols. Examples of lipids which have been used as meltable excipients are fatty acids, e.g. stearic acid, long chain alcohols, e.g.
  • cetostearyl alcohol naturally occurring and synthetic waxes, glyceryl esters of fatty acids, e.g glyceryl monostearate, glyceryl distearate, or glyceryl tristearate, aliphatic hydrocarbons, e.g. hard paraffin, polyglycerol esters of fatty acids, and any mixture thereof.
  • a release-modifying agent preferably a lipid
  • a melting point in the range of from about 10°C up to about 200°C, suitably from 20°C up to 150°C, and preferably 30°C up to 100°C.
  • the compact members may contain up to about 10 %, and preferably up to 5 % by weight of talc. Also, the compact members may contain up to about 5 %, suitably up to about 1 %, and preferably up to 0.5 % by weight of a lubricant. Suitably, use is made of magnesium stearate, which is a conventional and economic choice.
  • the PCMs can be made from a wide variety of cellulose raw materials.
  • the cellulose raw material is substantially pure, preferably of a pharmaceutical purity grade.
  • one or more chemically modified derivatives of cellulose as raw material, such as carboxy methylcellulose (CMC), alkylcelluloses, e.g. methylcellulose or ethylcellulose, hydroxypropylcellulose (HPC) or alkyl hydroxyalkyl celluloses, e.g. ethyl hydroxyethylcellulose (EHEC), optionally in any mixture with cellulose.
  • CMC carboxy methylcellulose
  • HPC hydroxypropylcellulose
  • EHEC alkyl hydroxyalkyl cellulose
  • the release-modifying agent is incorporated in the pores of the PCMs by any method suitable for the release-modifying agent at issue.
  • a melt process would be preferable, i.e. the lipid would be melted before incorporation.
  • the active compounds contained in the compact members of the present inven- tion are preferably drugs (pharmaceuticals).
  • the present invention is suitable for hydro- philic drugs, i.e. drugs soluble in water or aqueous solutions. Furthermore, the present invention is particularly useful for drugs exhibiting a biological half-life of less than about 20 hours, since extended release of drugs with a longer biological half-life is normally not necessary.
  • the present invention is preferably used for drugs exhibiting a biological half-life of less than 15 hours, and more preferably less than 10 hours. It should be recognized that the active compound to be incorporated in the compact members of the present invention may be any of a number of different compounds for different uses apart from drugs, e.g. fertilizers, pesticides, herbicides etc.
  • the compact members of the present invention may contain up to about 50 % by weight of the active compound, suitably up to 10 %, and preferably up to 2.5 % by weight of the active compound.
  • the PCMs can be exposed to the active compound and release-modifying agent in optional order, or preferably simultaneously, after premixing of the active compound and release- modifying agent.
  • the active compound and release-modifying agent can be dry mixed, as disclosed in Example 1 of the present specification. Other types of mixing are conceivable, and for the purpose of this invention, the term mixing would encompass any form of dispersing, suspending, emulsifying etc. which reasonably homogeneously would distribute the active compound in a release-modifying agent.
  • the amount of active compound and release-modifying agent necessary to fill the pores to a preselected level for a given batch is calculated from the densities of the active compound and release-modifying agent and the known pore volume for a given amount of PCMs.
  • the porosity of pure PCMs can be calculated from pellet density data measured by mercury porosimetry and from apparent density data obtained by helium pycnometry.
  • the pores are filled with the active compound and release-modifying agent to at least about 50% of the pore volume, preferably at least 70%, and more preferably at least 80% of the pore volume, before compacting the PCMs.
  • the PCMs comprising an active compound and a release-modifying agent are compacted to a desired shape.
  • desired shapes of compact members are cylindrical, cylindrical with rounded upper and lower surfaces, cubical and essentially spherical.
  • the pressure in the compacting step is suitably less than about 500 MPa, preferably in the range of from 10 up to 200 MPa, and more preferably in the range of from 50 up to 150 MPa.
  • compact members such as tablets, exhibit disintegration times in-vitro of less than about 240 minutes.
  • the disintegra- tion time in-vitro is suitably less than 90 minutes, and preferably less than 60 minutes.
  • Radial tensile strength is an important property for the compact members of the invention, since the radial tensile strength is a measure of the cohesive properties of the compact members, e.g. tablets.
  • the radial tensile strength of the compact member of the present invention can be higher than about 0.1 MPa, suitably higher than 0.3 MPa, and preferably higher than 0.5 MPa.
  • Example 1 (not according to the invention) A multiple-unit extended release matrix preparation, was prepared by the incorporation of a hydrophilic drug (Paracetamol; Hoechst, Germany) and lipophilic release modifiers (Cetanol; Bionord AB, Sweden, and hard paraffin; MB Sveda, Sweden) into porous cellulose matrices (PCMs).
  • a hydrophilic drug Paracetamol; Hoechst, Germany
  • lipophilic release modifiers Cetanol; Bionord AB, Sweden, and hard paraffin; MB Sveda, Sweden
  • PCMs porous cellulose matrices
  • the PCMs were made according to the method disclosed in WO-A-94/23703.
  • the drug was micronized and dry mixed with a lipid, using a mortar and a pestle.
  • the drug and lipid mixture was then heated on a water bath and the drug was thereby dispersed substantially homogeneously in the molten lipid.
  • PCMs were added during stirring. It is also conceivable to add the drug to the molten lipid, or vice versa.
  • the mixtures were allowed to cool during stirring.
  • the size fractions 0.5 - 0.71, 0.71 - 1.2 and 1.2 - 1.4 mm were obtained by sieving. Two pellets with no cellulose were also prepared for comparison.
  • the various formulations are shown in Table 1. TABLE 1 Prepared pellets and results from linear regression of ln(released drug) vs ln(time) for ⁇ 60% drug released for studied pellets. Lipid concentration is 43 % (w/w) unless otherwise indicated.
  • filled squares represent PCM and pure hard paraffin
  • filled triangles represent PCM and 1:1 of hard paraffi cetanol
  • filled circles represent PCM and 1 :2 of hard paraffimcetanol
  • empty triangles represent PCM and 1 :3 of hard paraffimcetanol
  • empty squares represent PCM and pure cetanol
  • empty circles represent reference pellets without cellulose matrix, i.e. pure lipid.
  • the in-vitro drug release could be extended over at least 16 hours.
  • the release rate could be controlled by varying the ratio of cetanol to paraffin.
  • Paracetamol (Hoechst, Germany) was chosen as a model drug substance since it is relatively stable and non-toxic and since it has been used in earlier studies. Cetanol (Bionord AB, Sweden) and hard paraffin (MB Sveda, Sweden) was used as release-modifying lipids.
  • Magnesium stearate (Kebo, Sweden) was used as model lubricant.
  • Anhydrous silicon dioxide (Aerosil, Degussa AG, Germany) and talc (Kebo, Sweden) were used as anti-adherents.
  • PCMs were manufactured from cellulose using a special process involving mechanical treatment in the presence of water (WO 94/23703). The size fraction 0.71- 1.17 mm was obtained by sieving.
  • Paracetamol and drug-and-lipid mixtures were incorporated into PCMs by the melting procedure as described in Example 1.
  • the composition used contains 54 % (w/w) cellulose, 43 % (w/w) lipid (cetanol: paraffin 2:1) and 2.5 % (w/w) paracetamol.
  • the loading was performed in subbatches of 150 g. Five subbatches were then poured into a polyethylene bag and mixed by hand shaking.
  • the porosity of pure PCMs was determined to be 54%. The porosity was calculated from pellet density data measured by mercury porosimetry and from apparent density data obtained by helium pycnometry. Some of the drug-and-lipid loaded PCMs were mixed, for 60 minutes, with magnesium stearate, talc and/or anhydrous silicon dioxide in a Turbula Mixer (2 liters, W. A. Bachofen, Switzerland). The batch size of the mixtures was 50 - 100 g.
  • the constant tensile strength at compaction pressures above 50 MPa could be due to the fact that no further deformation of the lipid is possible and that bonds have formed through all lipid material in the tablet. Some adherence of lipid material to the punch faces support the idea/suspicion that bonds may form due to partial melting or advanced diffusion during compaction. The assumption that bonds may have been formed is also supported by the low melting point of the lipids: 49.5°C for cetanol and 50 - 62°C for hard paraffin. Another explanation for the constant tensile strength above 50 MPa could be the fact that increased elastic expansion is cancelling out the effect of an increased volume reduction.
  • the lipids appear to act as lubricants. It is not absolutely necessary to add magnesium stearate for the tablets to be ejected from the die. However, an antiadhesion agent may be needed in some instances.
  • the friability of a compact member of the invention is defined as the amount of material attrited in a friabilator according to the procedure described below.
  • the friability of the tablets was measured in a friabilator model TA3 (Erweka Apparatebau, Germany). A pre-weighed sample of 10 tablets was rotated for 100 turns at a speed of 25 rpm and the amount of attrited material was determined gravimetrically. The friability expressed as a percentage was then calculated, and shown in Table 2b.
  • Friability values for pellets compressed at 12 and 200 MPa, respectively, with and without some additives are provided.
  • PCMs and mixtures of PCMs with additives was tableted in the single punch press at 12 and 200 MPa ( ⁇ 10 %) with automatic feeding and at a rate of approx. 37 tablets/minute. At least 25 tablets were compressed until constant ejection forces were obtained. The maximum upper and lower punch pressures and the ejection forces were then recorded for 10 tablets. The mean height of the tablets were measured after compression. The difference between maximum upper and lower punch pressures per tablet area in contact with the die (FD/A) and the ejection force per tablet area in contact with the die (EjF/A) were then calculated. These have been suggested as the most useful parameters for the study of friction during compaction. The height of the tablets after ejection was used as an estimate of height of the tablet in the die. Table 3 shows the results of the evaluation of friction characteristics for different formulations.
  • the disintegration time in deionized water was measured in an Erweka ZT 3 (Erweka Apparatebau, Germany) according to the USP method with discs.
  • the in-vitro drug release rates were determined according to USP method II (paddle) in deionized water, at 37°C with spectrophotometric detection. The stirring speed was 200 rpm.
  • the USP method II (paddle) was used since preliminary trials showed that the tablets did not disintegrate if USP method I (basket) was used. How- ever, in order to study the effect of tablet disintegration on drug release some tests using the basket method at 100 rpm were performed.
  • One tablet or approximately 360 mg pellets were added to each vessel with 900 ml water. This amount was chosen in order to maintain sink condition during the experiment.
  • Fig. 4 The effect on release rate of compaction pressure and thus disintegration time, is shown in Fig. 4, by comparing the release rates using the two methods USP I (basket) at 100 rpm, and USP II (paddle) at 200 rpm.
  • circles represent tablets compressed at 12 MPa and tested in USP apparatus II (filled circles), and the same tablets tested in USP apparatus I (empty circles), respectively.
  • Squares represent tablets compressed at 200 MPa and tested in USP apparatus II (filled) and USP apparatus I (empty), respectively.
  • Fig. 5 wherein release rates for tablets compressed at various pressures are shown as a function of time. The tests were performed using the USP II method at 200 rpm.
  • empty circles and empty triangles represent tablets compressed at 12 MPa and 20 MPa, respectively.
  • Empty squares and filled squares represent tablets compressed at 35 MPa and 100 MPa, respectively.
  • Filled circles and filled triangles represent tablets compressed at 200 MPa and uncompressed pellets, respectively.
  • the increase in release rate at low pressures may be due to some lipid being squeezed out of the PCMs during compression, increasing the porosity and surface area of the pellets.
  • lipid may be squeezed back into the pores of the PCMs.
  • some of the drug is redistributed and less drug may be exposed at the surfaces of the PCMs.
  • the incorporation process may cause a higher drug concentration close to the surface of the PCMs than in the centre of the matrices.
  • higher compaction pressures may increase the number of small agg- lomerates of spheres, which do not deagglomerate upon tablet disintegration. Consequently, the surface area of the matrices will decrease.
  • the higher release rate in the presence of additives may be due to the added substances forming a coating layer around the pellets. This coating layer may then either prevent the formation of non-disintegrating agglomerates or influence the redistribution of drug particles during compression.
  • Another possible explanation for the increased release rate is that hydrophilic additives are pressed into the matrix pellets thereby increasing their hydrophilicity. This may be a possible mechanism for silicon dioxide but seems less probable for talc and magnesium stearate.
  • extended release matrix pellets prepared by incorporation of release modifiers, especially lipids, into PCMs can be compacted into disintegrating tablets without the addition of any excipients.
  • the release rate is increasing at low compaction pressures and decreasing at higher pressures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne un élément compact composé d'une pluralité de matrices poreuses en cellulose (PCM) et permettant de libérer de façon prolongée un composé actif situé dans les pores desdites matrices avec un agent modifiant la libération. Le caractère friable de cet élément compact est inférieur à 2,1 % et le temps de désintégration in vitro dudit élément compact est inférieur à 240 minutes. On fabrique cet élément compact par exposition d'une pluralité de matrices poreuses (PCM) à un composé actif et à un agent modifiant la libération, dans une séquence ou dans un mélange éventuels, pendant une durée suffisante au remplissage des pores dans lesdites matrices jusqu'à un niveau présélectionné, par ledit composé actif et par ledit agent modifiant la libération. On rend ensuite ces matrices compactes jusqu'à obtention de la forme souhaitée. L'invention concerne, de plus, l'utilisation d'éléments compacts pour l'administration d'un médicament.
PCT/SE1997/001901 1996-11-12 1997-11-12 Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation WO1998020858A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ335737A NZ335737A (en) 1996-11-12 1997-11-12 Compact member comprising a plurality of porous cellulose matrices (PCMs)
AU50758/98A AU728754B2 (en) 1996-11-12 1997-11-12 Compact member comprising a plurality of porous cellulose matrices, (PCMs), method of manufacturing and use thereof
CA002271652A CA2271652A1 (fr) 1996-11-12 1997-11-12 Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation
EP97913618A EP0941069A1 (fr) 1996-11-12 1997-11-12 Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation
JP52247998A JP2001503766A (ja) 1996-11-12 1997-11-12 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9604124A SE9604124D0 (sv) 1996-11-12 1996-11-12 Compact member, method of manufacturing and use thereof
SE9604124-9 1996-11-12
US3172396P 1996-11-25 1996-11-25
US60/031,723 1996-11-25

Publications (1)

Publication Number Publication Date
WO1998020858A1 true WO1998020858A1 (fr) 1998-05-22

Family

ID=26662794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1997/001901 WO1998020858A1 (fr) 1996-11-12 1997-11-12 Element compact compose d'une pluralite de matrices poreuses en cellulose (pcm), son procede de fabrication et d'utilisation

Country Status (6)

Country Link
EP (1) EP0941069A1 (fr)
JP (1) JP2001503766A (fr)
AU (1) AU728754B2 (fr)
CA (1) CA2271652A1 (fr)
NZ (1) NZ335737A (fr)
WO (1) WO1998020858A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044353A1 (fr) * 1999-01-29 2000-08-03 Losan Pharma Gmbh Compositions pharmaceutiques
JP2003501377A (ja) * 1999-06-07 2003-01-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
US7001475B2 (en) 2001-12-11 2006-02-21 3M Innovative Properties Company Film structures and methods of making film structures
DE102005028696A1 (de) * 2005-06-21 2006-12-28 Pulmotec Gmbh Verwendung eines Hilfsstoffs zur Einstellung der Abrasionsfestigkeit eines verfestigten Wirkstoffpräparats
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8173161B2 (en) 2002-12-04 2012-05-08 Mcneil-Ppc, Inc. Method of administering a pharmaceutical active ingredient
US8617598B2 (en) 2001-09-28 2013-12-31 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009028598A1 (fr) * 2007-08-31 2009-03-05 Daiichi Sankyo Company, Limited Préparation à libération prolongée et procédé de fabrication de celle-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018590A1 (fr) * 1990-06-06 1991-12-12 Kabi Pharmacia Ab Procede de fabrication de matrices cellulosiques poreuses
WO1991019483A1 (fr) * 1990-06-20 1991-12-26 Advanced Polymer Systems, Inc. Compositions et procedes pour la liberation controlee de substances actives solubles
WO1994023703A1 (fr) * 1993-04-14 1994-10-27 Pharmacia Ab Fabrication de matrices

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018590A1 (fr) * 1990-06-06 1991-12-12 Kabi Pharmacia Ab Procede de fabrication de matrices cellulosiques poreuses
WO1991019483A1 (fr) * 1990-06-20 1991-12-26 Advanced Polymer Systems, Inc. Compositions et procedes pour la liberation controlee de substances actives solubles
WO1994023703A1 (fr) * 1993-04-14 1994-10-27 Pharmacia Ab Fabrication de matrices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, Volume 100, 1993, RICARDO DAVIDSON et al., "Porous Cellulose Matrices - A Novel Excipient for the Formulation of Solid Dosage Forms", pages 49-54. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044353A1 (fr) * 1999-01-29 2000-08-03 Losan Pharma Gmbh Compositions pharmaceutiques
US6962717B1 (en) 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
JP2003501377A (ja) * 1999-06-07 2003-01-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
JP4980527B2 (ja) * 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
US8617598B2 (en) 2001-09-28 2013-12-31 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
US7001475B2 (en) 2001-12-11 2006-02-21 3M Innovative Properties Company Film structures and methods of making film structures
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8173161B2 (en) 2002-12-04 2012-05-08 Mcneil-Ppc, Inc. Method of administering a pharmaceutical active ingredient
DE102005028696A1 (de) * 2005-06-21 2006-12-28 Pulmotec Gmbh Verwendung eines Hilfsstoffs zur Einstellung der Abrasionsfestigkeit eines verfestigten Wirkstoffpräparats

Also Published As

Publication number Publication date
AU5075898A (en) 1998-06-03
CA2271652A1 (fr) 1998-05-22
AU728754B2 (en) 2001-01-18
JP2001503766A (ja) 2001-03-21
NZ335737A (en) 2000-09-29
EP0941069A1 (fr) 1999-09-15

Similar Documents

Publication Publication Date Title
US4748023A (en) Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
US4708874A (en) Devices for the controlled release of active substances, as well as process for the preparation thereof
US5780055A (en) Cushioning beads and tablet comprising the same capable of forming a suspension
Soppimath et al. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: characterization and release kinetics of microspheres and tableted microspheres
CA2084680C (fr) Procede de fabrication de matrices cellulosiques poreuses
US8703203B2 (en) Oral dosage form of deferasirox
JP2008510000A (ja) 制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
JPH0830007B2 (ja) 徐放性カプセル
US7364755B2 (en) Modified calcium phosphate excipient
US20130039982A1 (en) Low-dose tablets and preparation process
WO2001003674A1 (fr) Procede de production de preparations pharmaceutiques solides se desagregeant rapidement
AU728754B2 (en) Compact member comprising a plurality of porous cellulose matrices, (PCMs), method of manufacturing and use thereof
US6322813B1 (en) Compact member, method of manufacturing and use thereof
JP2001335469A (ja) 固体製剤の製造方法
US20060115524A1 (en) Method for preparation of an agglomerate using melt agglomeration
Karasulu et al. Sustained release bioadhesive effervescent ketoconazole microcapsules tabletted for vaginal delivery
JPH02184624A (ja) トリメブチンを基剤とした徐放性組成物とその製造方法
de Abreu Pinto Formulation and tabletting of controlled release pellets produced by extrusion/spheronisation
Mohammed et al. Effect of a co-processed excipient on the disintegration and drug release profile of ibuprofen tablets
KR950007097B1 (ko) 서방성 캡슐
Bashaiwoldu Studies on the influence of composition and processing on the mechanical properties of pellets and compacted pellets
Louw Evaluation and comparison of magnesium stearate and sodium stearyl fumarate (Pruv) as lubricants in directly compressible tablet formulations: their effect on tablet properties and drug dissolution
Van der Merwe Effect of powder particle and punch type on the physical and compaction properties of tablets
Shah Preparaton and evauation of tableted microspheres of ibuprofen encapsulated in beeswax
Esterhuizen-Rudolph Development of a compressed bead-in-capsule drug delivery system for sustained release

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 50758/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 1998 522479

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2271652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 335737

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997913618

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997913618

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 50758/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1997913618

Country of ref document: EP